This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Experts urge early detection & better access to care
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Subscribe To Our Newsletter & Stay Updated
